Datopotamab deruxtecan showed promising responses as monotherapy and in combination with Imfinzi in patients with metastatic triple-negative breast cancer in two early trials
AstraZeneca and Daiichi Sankyo’s TROP2-directed ADC showed an encouraging objective response rate of 32% and a manageable safety profile in patients with metastatic TNBC in TROPION-PanTumor01 Phase I trial. Datopotamab deruxtecan plus Imfinzi demonstrated promising updated results with an objective response rate of 73.6% in 1st-line treatment of patients with metastatic TNBC in BEGONIA Phase Ib/II trial.Updated results from the TROPION-PanTumor01 Phase I trial showed datopotamab deruxtecan (Dato-DXd) continued to demonstrate encouraging responses in patients with heavily pretreated